3 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow TAK-041: new trials by email Literature Review of TAK-041 trials Research Report on TAK-041
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD Placebo, NBI-1065846 - Anhedonia, Major Depressive Disorder | Phase 2 | Completed | Neurocrine Biosciences | 93 | 2021-11-30 | 2024-07-31 |
| A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia TAK-041, Placebo, Second Generation Antipsychotics (SGA) - Stable Schizophrenia | Phase 2 | Completed | Neurocrine Biosciences | 23 | 2017-12-21 | 2021-03-19 |
| Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study TAK-041, TAK-041 Placebo - Healthy Volunteers, Schizophrenia | Phase 1 | Completed | Neurocrine Biosciences | 114 | 2016-05-09 | 2021-03-19 |
Anhedonia (1) · Depression (1) · Depressive Disorder, Major (1) · Schizophrenia (1)
United States (2) · Puerto Rico (1) · United Kingdom (1)
2017 (1)